{"eventGroups":[{"description":"Patients receive obatoclax mesylate IV over 3 hours and bortezomib (1.3 mg/m\\^2) IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"EG000","otherNumAffected":10,"otherNumAtRisk":10,"seriousNumAffected":3,"seriousNumAtRisk":10,"title":"Treatment (Enzyme Inhibitor Therapy)"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":10,"numEvents":36}],"term":"Hemoglobin decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10,"numEvents":1}],"term":"Cardiac disorder"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10,"numEvents":1}],"term":"Diplopia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":10,"numEvents":2}],"term":"Constipation"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":10,"numEvents":12}],"term":"Diarrhea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":10,"numEvents":7}],"term":"Nausea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":10,"numEvents":3}],"term":"Vomiting"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":10,"numEvents":6}],"term":"Fatigue"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10,"numEvents":1}],"term":"Hypersensitivity"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":10,"numEvents":27}],"term":"Leukocyte count decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":10,"numEvents":4}],"term":"Lymphocyte count decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":10,"numEvents":26}],"term":"Neutrophil count decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":10,"numEvents":23}],"term":"Platelet count decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":10,"numEvents":2}],"term":"Anorexia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":10,"numEvents":10}],"term":"Myalgia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10,"numEvents":1}],"term":"Ataxia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10,"numEvents":1}],"term":"Depressed level of consciousness"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10,"numEvents":1}],"term":"Dizziness"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10,"numEvents":1}],"term":"Extrapyramidal disorder"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":10,"numEvents":9}],"term":"Headache"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":10,"numEvents":6}],"term":"Peripheral motor neuropathy"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":10,"numEvents":27}],"term":"Peripheral sensory neuropathy"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10,"numEvents":1}],"term":"Speech disorder"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":10,"numEvents":4}],"term":"Anxiety"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10,"numEvents":2}],"term":"Depression"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":10,"numEvents":6}],"term":"Euphoria"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":10,"numEvents":3}],"term":"Psychosis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":10,"numEvents":15}],"term":"Dyspnea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10,"numEvents":1}],"term":"Hypoxia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10,"numEvents":1}],"term":"Pulmonary fibrosis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":10,"numEvents":2}],"term":"Rash desquamating"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":10,"numEvents":2}],"term":"Neutrophil count decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10,"numEvents":1}],"term":"Depressed level of consciousness"}]}